The pharma industry's latest comings and goings; why so few get screened for lung cancer

Taking stock of the drug industry, from the lab to the medicine chest

August 18, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Why so few get screened for lung cancer, the deadliest cancer in the U.S. A combination of strict eligibility criteria and special coverage requirements means few at high risk get lung cancer screening. By Simar Bajaj Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch STAT's Jason Mast joins us to explain how a gene therapy set in motion a frantic race to get children treated before their 6th birthdays. By Damian Garde and Allison DeAngelis and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser